Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

Laboratory of Tissue Regeneration and Immunology and Department of Periodontics, Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, School of Stomatology, Capital Medical ...

This effect was not observed when MARCO was targeted alongside anti-PD1 therapy, emphasizing the ... regression and immune ...

NESS-ZIONA, Israel I April 03, 2025 I Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming ...

Bregenholt hopes that with this approach Macrophage, and its lead product MPL5821, could help pharma to overcome some of the issues that still dog checkpoint inhibitor therapy. While these drugs ...

Researchers have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor ... of immunotherapy known as anti-CTLA4 therapy, significantly enhances tumor ...

This study provides proof-of-principle data for the use of trained immunity to modulate macrophage interactions with tumours. The study makes a valuable contribution to the field of trained immunity.

One of the worst complications of adult-onset Still's disease is macrophage activation syndrome (MAS), which can be fatal. In ...